OncoMatch/Clinical Trials/NCT06984146

Nivo40-AVD for Advanced Classic Hodgkin Lymphoma

Is NCT06984146 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Nivolumab and Doxorubicin for hodgkin lymphoma, adult.

Phase 2RecruitingNational Medical Research Radiological Centre of the Ministry of Health of RussiaNCT06984146Data as of May 2026

Treatment: Nivolumab · Doxorubicin · Vinblastine · Dacarbazine — The aim of the current trial is to evaluate the efficacy and safety of flat-dose nivolumab (40 mg) in combination with AVD in the management of patients with newly diagnosed advanced classic Hodgkin Lymphoma

Check if I qualify

Extracted eligibility criteria

Cancer type

Hodgkin Lymphoma

Disease stage

Required: Stage IIB, III, IV

Performance status

ECOG 0–4(Completely disabled)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Kidney function

creatinine <= 2x uln

Liver function

alt or ast <= 5x uln; bilirubin <= 2x uln

Cardiac function

ejection fraction > 50%

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify